These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20191897)

  • 1. [Expression of CA-125 in ovarian cancer].
    Mircea R; Frîncu DL; Dumitrache F
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
    Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
    Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
    Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A step forward for two-step screening for ovarian cancer.
    Hensley ML
    J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
    [No Abstract]   [Full Text] [Related]  

  • 5. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ovarian neoplasms and tumor markers].
    Zarcone R; Candido R; Cardone G; De Luca P; Voto RI; Bellini P
    Minerva Ginecol; 1994 Oct; 46(10):531-3. PubMed ID: 7838408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
    Shi W; Zhang YJ; Jiang CY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalizing ovarian cancer screening.
    Goozner M
    J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
    [No Abstract]   [Full Text] [Related]  

  • 15. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
    But I; Gorisek B
    Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
    Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. StatBite: Ovarian cancer: risk of recurrence by stage of diagnosis.
    J Natl Cancer Inst; 2009 Sep; 101(18):1234. PubMed ID: 19738164
    [No Abstract]   [Full Text] [Related]  

  • 18. CA-125 level preoperative assessment in early and advanced ovarian carcinoma.
    Raspollini MR
    Gynecol Oncol; 2007 Nov; 107(2):356-7; author reply 357-8. PubMed ID: 17716712
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
    Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Facchini V; Genazzani AR
    Anticancer Res; 1995; 15(6B):2683-6. PubMed ID: 8669847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.